Piper Sandler Assumes Travere Therapeutics at Neutral, Announces Price Target of $22
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Nicole Gabreski assumes Travere Therapeutics (NASDAQ:TVTX) with a Neutral rating and announces a price target of $22.
June 07, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler analyst Nicole Gabreski gives Travere Therapeutics a Neutral rating and sets a price target of $22.
The news directly mentions Travere Therapeutics (TVTX) and the Neutral rating given by Piper Sandler analyst Nicole Gabreski. The price target of $22 is also announced, which may influence the stock price in the short term. However, the Neutral rating suggests that the stock price may not experience significant movement in either direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100